Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of lacosamide in amyotrophic lateral sclerosis
jRCTs031180173Completed
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lacosamide in amyotrophic lateral sclerosis (ALS). Primary endpoint: Safety for 5 weeks. Started Jul 2017; status: completed.
02
Drugs
lacosamide
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCTs031180173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180173.